Pancreatic Cancer Metastatic clinical trials

Explore recruiting pancreatic cancer metastatic clinical trials.

Recruiting pancreatic cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pancreatic Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.

Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy

Germany, Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pancreatic Cancer Metastatic trials by city

Pancreatic Cancer Metastatic clinical trials

Recruiting pancreatic cancer metastatic studies right now

Intravital Microscopy in Human Solid Tumors

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

Also recruiting in Europe

Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced Pancreatic Cancer

A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)

Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study

Pancreatic Cancer Metastatic trials by city

Other conditions